위암 치료제 시장 세계 시장 규모는 2024년 52억 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2033년까지 135억 달러에 달하고, 2025년부터 2033년까지 10.7%의 연평균 성장률(CAGR)을 보일 것으로 예측했습니다. 노령 인구의 확대와 전 세계 비만 증가가 시장을 자극하고 있습니다.
위암 치료제는 위 점막에 악성 세포가 형성되는 위암 진단을 받은 환자를 완화하거나 치료하기 위해 개발된 의약품입니다. 위암의 일반적인 증상으로는 원인 불명의 체중 감소, 소화 불량, 복부 팽만감, 메스꺼움, 구토, 속쓰림, 음식물 삼키기 어려움 등이 있습니다. 독소루비신 염산염, 수니티닙, 마이토마이신, 플루오로라실, 이마티닙, 도세탁셀 등이 일반적으로 사용되는 위암 치료제입니다. 이들 약제는 암세포의 일부를 사멸시켜 종양을 축소시키고 암의 징후와 증상을 완화하는 데 도움이 됩니다. 또한 암세포의 증식, 분열, 세포 증식을 억제하는 작용도 합니다. 그 결과, 위암 치료제는 경구용 또는 비경구용 약물로 투여되며 병원, 클리닉, 특수 치료 센터에서 사용되고 있습니다.
노인 인구 증가와 전 세계 비만 유병률 증가는 주로 시장 성장의 원동력이 되고 있습니다. 이와 함께, 건강에 해로운 식습관과 좌식 생활로 인한 체중 관련 건강 문제가 증가함에 따라 시장 성장을 가속하고 있습니다. 또한, 담배와 알코올 음료 소비 증가로 인한 암 증가와 예방 및 치료 약물에 대한 수요 증가도 성장을 가속하는 요인으로 작용하고 있습니다. 이와는 별도로, 종양 성장을 억제하는 두 가지 위암 바이오마커의 도입은 시장 성장에 탄력을 받고 있습니다. 또한, 제조업체들은 위 침식이나 메스꺼움과 같은 부작용을 최소화한 제품 개발에 주력하고 있으며, 이는 시장 성장을 가속하고 있습니다. 이와 함께, 효과적이고 특화된 암 치료제의 개발에 초점을 맞춘 급속한 기술 발전은 시장에 밝은 전망을 가져다주고 있습니다. 또한, 주요 제약회사와 주요 업체들은 더 안전하고, 더 효과적이며, 경제적으로 실행 가능하고, 더 쉽게 투여할 수 있는 위암 치료제를 개발하기 위해 연구 개발(R&D) 활동에 많은 투자를 하고 있습니다. 이와 더불어, 제조업체가 생산하는 의약품의 품질을 보장하기 위해 의약품의 제조, 가공, 포장을 촉진하는 다양한 정부 이니셔티브가 시행되고 있는 것도 시장 성장에 긍정적인 영향을 미치고 있습니다. 의료비 지출 증가, 위암의 증상 및 치료 옵션에 대한 소비자의 인식 증가와 같은 다른 요인들도 시장 성장을 가속할 것으로 예상됩니다.
The global gastric cancer drugs market size reached USD 5.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 13.5 Billion by 2033, exhibiting a growth rate (CAGR) of 10.7% during 2025-2033. The expanding geriatric population and the rising incidence of obesity across the world are stimulating the market.
Gastric cancer drugs are medications developed to relieve or treat an individual diagnosed with stomach cancer in which malignant cells form in the lining of the stomach. Some common symptoms of gastric cancer are unexplained weight loss, indigestion, bloating, nausea, vomiting, heartburn, and difficulty swallowing food. Doxorubicin hydrochloride, sunitinib, mitomycin, fluorouracil, imatinib, and docetaxel are commonly available gastric cancer drugs. They help to shrink a tumor and relieve signs and symptoms of cancer by killing some of the cancer cells. They also assist in reducing cancer cells from growing, dividing, and making more cells. As a result, gastric cancer drugs are administered through oral and parenteral forms and are used by hospitals, clinics, and special treatment centers.
The increasing geriatric population and the rising prevalence of obesity across the globe are primarily driving the market growth. In line with this, the growing incidences of weight-related health concerns due to unhealthy eating habits and sedentary lifestyles are favoring the market growth. Moreover, the increasing cases of cancer, due to the rising consumption of tobacco-based products and alcoholic beverages, and the enhanced need need for preventive and therapeutic medications are acting as another growth-inducing factor. Apart from this, the introduction of two gastric cancer biomarkers that help in eliminating tumor growth is providing an impetus to the market growth. Moreover, manufacturers are focusing on creating product variants with minimal side effects, such as gastric erosion and nausea, thus propelling the market toward growth. Along with this, rapid technological advancements focusing on the development of effective and specific cancer treatments are creating a positive outlook for the market. Furthermore, leading pharmaceutical companies and key players are investing heavily in research and development (R&D) activities to develop gastric cancer drugs that are safer, more effective, economically viable, and easier to administer. Besides this, the implementation of various government initiatives to promote the manufacturing, processing, and packing of a drug product ensuring the quality of drugs produced by manufacturers is positively influencing the market growth. Other factors, including rising healthcare expenditure and growing consumer awareness regarding the symptoms and the available treatment options for gastric cancer, are anticipated to drive the market growth.
Type Insights
Doxorubicin Hydrochloride
Sunitinib
Docetaxel
Mitomycin
Fluorouracil
Imatinib
Trastuzumab
Route of Administration Insights
Oral
Parenteral
End User Insights
Hospitals
Clinics
Others
The report has also provided a detailed breakup and analysis of the gastric cancer drugs market based on the end user. This includes hospitals, clinics, and others. According to the report, hospitals represented the largest segment.
Regional Insights
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, Asia Pacific was the largest market for gastric cancer drugs. Some of the factors driving the Asia Pacific gastric cancer drugs market included its high healthcare expenditure, technological advancements, and rising geriatric population.
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global gastric cancer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Arog Pharamaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ono Pharmaceutical Co. Ltd., Sanofi S.A., Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.), etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report